publication date: Dec. 19, 2010

In this issue: 

Phase III trial shows benefit for old drugs, old device, for ovarian cancer, but will practice change?

NCI clinical alert urges patients to seek care from specialists.

FDA revises package insert, seeks to limit product liability suits in state courts.

Senate committee investigating pharma’s “educational grants.”

Download (PDF 886KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.